PEPTIDE-BASED CANCER VACCINES

The application of molecularly defined vaccines composed of a limited number of tumor-specific T cell epitopes has resulted in protective an titumor T cell immunity in several mouse tumor models. The first encou raging results with such vaccines have been obtained in human beings. The development of the next generation of rationally designed vaccines that are both effective and safe for application in a clinical settin g requires comparison of different modes of delivery of tumor-associat ed T cell epitopes in multiple epitope constructs.